10-K: Tenon Medical Reports 2025 Results, Nasdaq Listing Risk

Tenon Medical, Inc. reported increased revenue for 2025 but continues to face significant operating losses, a going concern doubt, and a Nasdaq delisting notice due to its low bid price.

Summary

• Revenue increased by 20% to $3.944 million in 2025 from $3.277 million in 2024.
• Gross profit increased by 38% to $2.358 million in 2025 from $1.711 million in 2024, with the gross profit percentage rising from 52% to 60%.
• Net loss decreased to $12.556 million in 2025 from $13.673 million in 2024.
• Operating expenses slightly decreased to $15.150 million in 2025 from $15.477 million in 2024.
• Acquired substantially all assets of SiVantage, Inc. and SIMPL Medical, LLC in August 2025, adding The SImmetry+ System to its product portfolio.
• Received a Nasdaq notice on February 25, 2026, for not maintaining a minimum closing bid price of $1.00, with a compliance period until August 24, 2026.
• Raised approximately $4.3 million in gross proceeds from a private placement of convertible promissory notes on March 11, 2026.
• The independent registered public accounting firm included an explanatory paragraph in its report on the financial statements for the fiscal year ended December 31, 2025, describing substantial doubt about the company's ability to continue as a going concern.
• The company had an accumulated deficit of $81.3 million as of December 31, 2025, and cash and cash equivalents of $3.8 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly concerning report, primarily due to the persistent operating losses, negative cash flow, the auditor's going concern warning, and the immediate threat of Nasdaq delisting. While revenue growth and product acquisitions show some operational progress, the fundamental financial instability and capital needs overshadow these positives.

Positives

• Revenue grew by 20% to $3.944 million in 2025, up from $3.277 million in 2024.
• Gross profit percentage improved significantly from 52% in 2024 to 60% in 2025.
• Net loss decreased by approximately $1.1 million, from $13.673 million in 2024 to $12.556 million in 2025.
• The acquisition of SiVantage, Inc. and SIMPL Medical, LLC in August 2025 expanded the product portfolio with The SImmetry+ System, offering a new minimally invasive lateral access solution.
• The FDA expanded the indication for The Catamaran System in March 2025 to augment immobilization and stabilization of the SI Joint in patients undergoing sacropelvic fixation as part of a lumbar fusion procedure.
• Ongoing post-market clinical studies for The Catamaran System (Mainsail Study) have shown statistically significant reduction in SI Joint pain at 12 months, a robust safety profile, high patient satisfaction, and definitive evidence of fusion.
• The SImmetry+ System's EVoluSIon study, one of the largest clinical datasets in minimally invasive SI Joint fusion, demonstrated statistically significant reductions in pain and disability, meaningful reductions in opioid use, and approximately 69% radiographic evidence of fusion on CT at 12 months.
• Successfully completed a private placement of convertible promissory notes in March 2026, raising approximately $4.3 million in gross proceeds.

Negatives

• The company has incurred recurring losses from operations and negative cash flows, raising substantial doubt about its ability to continue as a going concern.
• Received a Nasdaq notice on February 25, 2026, for failing to maintain a minimum closing bid price of $1.00, risking delisting if compliance is not regained by August 24, 2026.
• An accumulated deficit of $81.3 million as of December 31, 2025, indicates significant historical losses.
• Cash and cash equivalents of $3.8 million as of December 31, 2025, are not sufficient to fund operating expenses and working capital requirements for at least the next 12 months.
• Management identified a material weakness in internal control over financial reporting due to a lack of segregation of duties.
• The trading price of common stock has been highly volatile, ranging from a high of $12.80 to a low of $0.6659 per share between January 1, 2024, and March 27, 2026.
• The potential conversion of Series A and Series B Preferred Stock and the exercise of numerous outstanding warrants (totaling over 8 million shares underlying warrants and 1.8 million shares underlying preferred stock as of December 31, 2025) may cause significant dilution to existing stockholders.
• Several directors and executive officers did not comply with all Section 16(a) filing requirements for the fiscal year ended December 31, 2025, indicating potential governance oversight issues.

Risks

• Incurred losses in the past, financial statements prepared on a going concern basis, and may be unable to achieve or sustain profitability in the future.
• If hospitals, clinicians, and other healthcare providers are unable to obtain coverage and reimbursement from third-party payors for procedures performed using products, adoption may be delayed, and products may not gain further acceptance.
• May not be able to convince physicians that The Catamaran System and The SImmetry+ System are attractive alternatives to competitors' products and existing surgical and non-surgical treatments of the SI Joint.
• Clinicians and payors may not find clinical evidence compelling, which could limit sales, and ongoing and future research may prove products less safe and effective than initially anticipated.
• Pricing pressure from competitors, changes in third-party coverage and reimbursement, healthcare provider consolidation, payor consolidation, and the proliferation of physician-owned distributorships may impact the ability to sell products at necessary prices.
• Operates in a very competitive business environment; inability to compete successfully against existing or potential competitors could negatively affect sales and operating results.
• Currently manufactures (through third parties) and sells products used in a single procedure, which could negatively affect operations and financial condition.
• Dependent on a limited number of contract manufacturers, some single-source and some in single locations; loss or inability to provide adequate supply could materially adversely affect business.
• Subject to extensive governmental regulation both in the United States and abroad; failure to comply could cause business to suffer.
• Independent sales representatives must comply with U.S. federal and state fraud and abuse laws, including those relating to physician kickbacks and false claims for reimbursement.
• Inability to protect the confidentiality of trade secrets could harm business and competitive position.
• May incur product liability losses, and insurance coverage may be inadequate or unavailable to cover these losses.
• Increasingly dependent on information technology; systems and infrastructure face certain risks, including cybersecurity and data leakage risks.
• The medical device industry is characterized by patent litigation; could become subject to costly litigation, diversion of management time, damages, and/or prevention from developing or marketing products.
• Business could suffer if key members of senior management, key advisors, or personnel are lost.
• Various factors outside direct control may adversely affect manufacturing and distribution of products.
• May seek to grow business through acquisitions or investments; failure to manage or integrate could have a material adverse effect.
• Ability to protect intellectual property and proprietary technology is uncertain.
• The size and future growth in the market for SI Joint fixation have not been established based on market reports, and estimates may be smaller than anticipated.
• Has a limited operating history and may face difficulties encountered by early-stage companies in new and rapidly evolving markets.
• Failure to adequately protect personal information in compliance with evolving legal requirements could harm business.
• Geopolitical conditions, including trade disputes and direct or indirect acts of war or terrorism, could have an adverse effect on operations and financial results.
• Inflation may adversely affect operations and financial results.
• Failure to maintain compliance with Nasdaq's continued listing standards or other requirements could result in common stock being delisted.
• Future sales of substantial amounts of common stock could adversely affect the market price.
• Series A Preferred Stock and Series B Preferred Stock rank senior to common stock.
• Conversion of Series A Preferred Stock, Series B Preferred Stock, or the exercise of various warrants may cause significant dilution to stockholders.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research, stock price and trading volume could decline.
• Failure to maintain effective internal control over financial reporting could have an adverse impact.
• May be subject to securities litigation, which is expensive and could divert management's attention.
• As an emerging growth company, reduced disclosure requirements may make common stock less attractive to investors.
• Has not paid dividends in the past and does not expect to pay dividends in the future; any return on investment may be limited to the value of stock.
• The elimination of personal liability against directors and officers under Delaware law and the existence of indemnification rights may result in substantial expenses.
• Certificate of Incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, which could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company expects operating expenses to increase in absolute dollars as it continues to invest in business growth, including building commercial infrastructure, developing and enhancing products, and expanding sales and marketing efforts. Research and development spending is also anticipated to rise due to product improvements, new product development, and clinical activities. While general and administrative expenses are expected to increase in absolute terms, they are projected to decrease as a percentage of revenue over time. The company plans to raise additional capital through public or private equity offerings, debt financings, and collaborations to fund its operations. Strategic plans include continuing post-market clinical research to confirm product benefits, expanding The Catamaran System offering with various sizes, broadening The SImmetry+ System implant portfolio, and advancing novel and potentially disruptive technology platforms for SI Joint treatment.

Management Comments

• "We are a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders."
• "We believe the SI Joint is the last major joint to be successfully addressed by the spine implant industry."
• "We believe that this multi-platform, multi-approach strategy strengthens Tenon's competitive advantage in the expanding SI Joint fusion market and underscores the Company's commitment to delivering effective, durable outcomes for physicians and patients."
• "Our business objective is to introduce the next generation of implants for SI Joint fixation and fusion."
• "Our strategy is to provide a safer, faster, and better surgical experience and a significant pain reduction benefit for the patient."
• "We believe that our ability to offer The Catamaran System implants in various sizes will benefit many patients requiring a revision surgery and thus reduce the associated challenges and variability found in this type of procedure."
• "Our mission continues to be developing enhancements to The Catamaran System and its instrument system to meet our customers changing needs and to improve the surgery's effectiveness."
• "Management believes that there is substantial doubt in our ability to continue as a going concern for the next twelve months from the issuance of these financial statements."
• "Our size has prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation of duties. Therefore, it is difficult to effectively segregate accounting duties which comprises a material weakness in internal controls."

Industry Context

StockSavvy.ai notes that the medical device industry, particularly for spine and orthopedic solutions, is highly competitive and characterized by rapid technological change. The SI Joint fixation market is described as 'vastly underserved' and 'only penetrated 5-7%', suggesting significant growth potential for innovative solutions. The company's strategy of offering multiple minimally invasive approaches (lateral and inferior-posterior) with robust clinical evidence aims to differentiate itself in a market where existing options have faced challenges with complexity, morbidity, and fusion confirmation. Consolidation among healthcare providers and payors, along with pricing pressures, are significant industry trends impacting market access and profitability for medical device companies.

Comparison to Industry Standards

• The largest clinical device supplier in the SI Joint market performs approximately 16,000 SI Joint fixations annually, holding the largest market share, while other competitive devices account for roughly 5,000 procedures.
• The Catamaran System is differentiated from competitors by its trans-articular placement, inferior-posterior approach, reduced morbidity, direct visualization, single implant technique, insertion trajectory away from neural foramen and major lateral vascular structures, autologous bone grafting, and radiographic confirmation of bridging bone fusion.
• An independent biomechanical study by Lisa Ferrara, Ph.D. of OrthoKinetic Technologies, LLC (now part of Element) demonstrated that a single Catamaran SIJ Fixation Device was superior to a predicate device in fixation strength, shear stiffness, dynamic endurance, and pullout strength.
• The SImmetry+ System's EVoluSIon study, involving up to 250 patients, is highlighted as one of the largest clinical datasets in minimally invasive SI Joint fusion, supporting its safety, effectiveness, and true fusion approach.
• The company believes that existing SI Joint treatment options suffer from complex surgical approaches and suboptimal implant designs, contributing to a low market penetration of 5-7%.

Management Changes

Corporate Governance

Related Party Transactions

• Richard Ferrari, Executive Chairman, has a Consulting Agreement (Ferrari Consulting Agreement) with compensation of $22,500 per month. He received a $350,000 bonus in April 2022 and RSUs with a grant date fair value of $2,427,020 in May 2022. Compensation paid to Mr. Ferrari during the fiscal years ended December 31, 2025 and 2024, totaled $247,500 and $270,000, respectively.
• Nathaniel Grawey, Chief Commercial Officer, purchased 101,167 shares of common stock and warrants to purchase up to 101,167 shares of common stock for a total of $130,000 in a PIPE transaction on November 10, 2025.
• Steven Foster, Chief Executive Officer, and Wyatt Geist, Chief Innovation Officer, also participated in the November 2025 PIPE Financing as investors.

Stakeholder Impact

• Shareholders face significant dilution risk from numerous outstanding warrants and convertible preferred stock, which could depress the market price of common stock.
• Shareholders are at risk of reduced liquidity and market price decline due to the Nasdaq delisting notice for failing to meet the minimum bid price requirement.
• Employees are impacted by the company's financial instability and the need to raise additional capital, which could affect future operations and job security.
• Customers (hospitals, clinicians) may be discouraged from adopting the company's products if third-party reimbursement remains inadequate or inconsistent, affecting product sales.
• Suppliers, particularly contract manufacturers, face risks due to the company's dependence on a limited number of them, potentially impacting supply chain stability.
• Creditors, specifically holders of the convertible promissory notes, are exposed to the company's ability to raise future capital for prepayments and the risk associated with the company's going concern status.

Next Steps

• Regain compliance with Nasdaq's minimum bid price rule by August 24, 2026, potentially through a reverse stock split.
• Raise additional capital through public or private equity offerings, debt financings, and collaborations to fund operations.
• Continue to build commercial infrastructure and invest in the independent sales representative network, including training.
• Develop and enhance existing products (The Catamaran System and The SImmetry+ System) and introduce new product advancements in the SI Joint and pelvic region.
• Execute post-market clinical research to confirm the benefits of the distinct approach and implant.
• Remediate the material weakness in internal control over financial reporting by increasing qualified financial personnel and improving segregation of duties.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by recurring losses, negative cash flows, an accumulated deficit of over $81 million, and an explicit 'going concern' warning from its auditor. The immediate threat of Nasdaq delisting due to a sub-$1.00 bid price, coupled with substantial dilution risk from numerous outstanding warrants and convertible securities, creates an extremely high-risk investment profile. While product acquisitions and clinical study results show some operational progress, the fundamental financial instability and urgent need for capital overshadow these positives, making the stock a strong sell for seasoned investors.

Keywords

Medical devices, SI Joint fusion, Catamaran System, SImmetry+ System, Sacroiliac joint, Spinal fusion, Orthopedics, Minimally invasive surgery, FDA clearance, Nasdaq delisting, Convertible notes, Equity financing, Healthcare technology, Financial reporting, Going concern, Intellectual property, Product liability, Cybersecurity